NCT07423078 2026-02-20
WOLF
University of Pittsburgh
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07088211 2025-07-31
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT06861712 2025-04-25
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06378177 2024-06-27
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
Lyvgen Biopharma Holdings Limited
Phase 2 Recruiting
NCT05773079 2024-04-01
Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT06081582 2023-10-13
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05993858 2023-08-15
PC-1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT04807140 2023-04-14
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT05803915 2023-04-07
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04523883 2021-04-15
IMPORT
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04164238 2019-11-15
Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown